Heart failure & cardiomyopathies

Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction

J Am Coll CardiolPublished Prespecified secondary analysis of the STEP-HFpEF randomised trial

Authors' conclusion

In patients with HFpEF and obesity, semaglutide 2.4 mg improved symptoms, physical limitations, and exercise function, and reduced inflammation and body weight to a similar extent across LVEF categories.

Study context

Population
Patients with the obesity phenotype of HF with preserved ejection fraction (HFpEF), categorised by left ventricular ejection fraction (LVEF) 45%–49%, 50%–59%, ≥60%categorised by LVEF 45%–49% 85 · 50%–59% 215 · ≥60% 229
Participants
529 patients
Comparison
Semaglutide vs placebo across baseline LVEF strata
  • Semaglutiden = 263
  • Placebon = 266reference
Primary endpoint
Dual primary endpoints: KCCQ Clinical Summary Score and body weight
Follow-up
52 weeks

Primary result

As reported in the abstract

Semaglutide vs PlaceboEstimated treatment difference, points (95% CI)P value
KCCQ-CSS, EF 45%-49%
5.0(−2.7 to 12.8)
KCCQ-CSS, EF 50%-59%
9.8(5.0–14.6)
KCCQ-CSS, EF ≥60%
7.4(2.8–12.0)
P = 0.56for interaction
Semaglutide vs PlaceboEstimated treatment difference (95% CI)P value
Body weight, EF 45%-49%
−7.6(−10.7 to −4.4)
Body weight, EF 50%-59%
−10.6(−12.6 to −8.6)
Body weight, EF ≥60%
−11.9(−13.8 to −9.9)
P = 0.08for interaction

Secondary outcomes

Confirmatory secondary and exploratory endpoints by LVEF category

LVEF did not influence benefit on 6-minute walk distance
P for interaction = 0.19
LVEF did not influence benefit on hierarchical composite endpoint
P for interaction = 0.43
LVEF did not influence benefit on hs-CRP
P for interaction = 0.26
LVEF did not influence benefit on NT-proBNP (exploratory)
P for interaction = 0.96

Safety

Tolerability

Semaglutide was well-tolerated across LVEF categories

Original publication

Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction. J Am Coll Cardiol. Published 8 October 2023. doi:10.1016/j.jacc.2023.09.811

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.